Table 1.
Antimicrobial Agent | Concentration (mg/L) | Qualitative Susceptibility* |
---|---|---|
Amikacin | 16 | Susceptible, ≤16 |
Amoxicillin/K Clavulanate | ≤8/4 | Susceptible, ≤8/4 |
Ampicillin/Sulbactam | >16/8 | Resistant, >16/8 |
Ampicillin | >16 | Resistant, >16 |
Aztreonam | 8 | Susceptible, ≤8 |
Cefazolin | >16 | Resistant, >16 |
Cefepime | >16 | Resistant, >16 |
Cefoxitin | ≤8 | Susceptible, ≤8 |
Cefotaxime | >32 | Resistant, >32 |
Cefotetan | ≤4 | Susceptible, ≤16 |
Ceftazidime | 8 | Susceptible, ≤8 |
Ceftizoxime | >32 | Resistant, >32 |
Ceftriaxone | >32 | Resistant, >32 |
Cefuroxime | >16 | Resistant, >16 |
Cefalotin | >16 | Resistant, >16 |
Chloramphenicol | ≤8 | Susceptible, ≤8 |
Gatifloxacin | ≤2 | Susceptible, ≤2 |
Gentamicin | 4 | Susceptible, ≤4 |
Levofloxacin | ≤2 | Susceptible, ≤2 |
Meropenem | ≤1 | Susceptible, ≤4 |
Nitrofurantoin | ≤32 | Susceptible, ≤32 |
Piperacillin | >64 | Resistant, >64 |
Piperacillin/Tazobactam | ≤8 | Susceptible, ≤8 |
Tetracycline | >8 | Resistant, >8 |
Ticarcillin/K Clavulanate | 32 | Intermediate, 32−64 |
Tobramycin | 8 | Intermediate, 8 |
Trimethoprim/Sulfamethoxazole | ≤2/38 | Susceptible, ≤2/38 |
The endpoint of susceptibility interpretation is indicated for each antibiotic.